SCI时时刷

search
+
Multinational retrospective analysis of bridging therapy prior to chimeric antigen receptor t cells for relapsed/refractory acute lymphoblastic leukemia in children and young adults
Multinational retrospective analysis of bridging therapy prior to chimeric antigen receptor t cells for relapsed/refractory acute lymphoblastic leukemia in children and young adults
Anti-CD19 chimeric antigen receptor T cells (CAR) are a well-established treatment option for children and young adults su...
Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition
Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition
The tumor microenvironment (TME) is integral to cancer progression, impacting metastasis and treatment response. It consis...
Global status and attributable risk factors of breast, cervical, ovarian, and uterine cancers from 1990 to 2021
Global status and attributable risk factors of breast, cervical, ovarian, and uterine cancers from 1990 to 2021
Female-specific cancers, particularly breast, cervical, ovarian, and uterine cancers, account for nearly 40% of all cancer...
D-ribose-5-phosphate inactivates YAP and functions as a metabolic checkpoint
D-ribose-5-phosphate inactivates YAP and functions as a metabolic checkpoint
Targeting glucose uptake by glucose transporter (GLUT) inhibitors is a therapeutic opportunity, but efforts on GLUT inhibi...
Impact of circulating lymphoma cells at diagnosis on outcomes in patients with newly diagnosed de novo diffuse large B-cell lymphoma
Impact of circulating lymphoma cells at diagnosis on outcomes in patients with newly diagnosed de novo diffuse large B-cell lymphoma
Diffuse large B-cell lymphoma (DLBCL), the most common B-cell non-Hodgkin lymphoma rarely presents with circulating lympho...
A phase II trial of anlotinib plus EGFR-TKIs in advanced non-small cell lung cancer with gradual, oligo, or potential progression after EGFR-TKIs treatment (CTONG-1803/ALTER-L001)
A phase II trial of anlotinib plus EGFR-TKIs in advanced non-small cell lung cancer with gradual, oligo, or potential progression after EGFR-TKIs treatment (CTONG-1803/ALTER-L001)
The study is to evaluate the efficacy and safety of combined anlotinib and EGFR-tyrosine kinase inhibitors (TKIs) in patie...
Dual inhibition of LAG-3 and PD-1 with IBI110 and sintilimab in advanced solid tumors: the first-in-human phase Ia/Ib study
Dual inhibition of LAG-3 and PD-1 with IBI110 and sintilimab in advanced solid tumors: the first-in-human phase Ia/Ib study
Co-inhibition of immune checkpoints lymphocyte-activation gene 3 (LAG-3) and PD-1 is believed to enhance cancer immunother...
Current and future immunotherapy for breast cancer
Current and future immunotherapy for breast cancer
Substantial therapeutic advancement has been made in the field of immunotherapy in breast cancer. The immune checkpoint in...
Lenvatinib and immune-checkpoint inhibitors in hepatocellular carcinoma: mechanistic insights, clinical efficacy, and future perspectives
Lenvatinib and immune-checkpoint inhibitors in hepatocellular carcinoma: mechanistic insights, clinical efficacy, and future perspectives
Lenvatinib is a multi-target tyrosine kinase inhibitor widely used in the treatment of hepatocellular carcinoma (HCC). Its...
myCAF-derived exosomal PWAR6 accelerates CRC liver metastasis via altering glutamine availability and NK cell function in the tumor microenvironment
myCAF-derived exosomal PWAR6 accelerates CRC liver metastasis via altering glutamine availability and NK cell function in the tumor microenvironment
Liver metastasis from colorectal cancer (CRC) is a major clinical challenge that severely affects patient survival. myofib...
Correction: Non-invasive diagnosis of esophageal cancer by a simplified circulating cell-free DNA methylation assay targeting OTOP2 and KCNA3: a double-blinded, multicenter, prospective study
Correction: Non-invasive diagnosis of esophageal cancer by a simplified circulating cell-free DNA methylation assay targeting OTOP2 and KCNA3: a double-blinded, multicenter, prospective study
Yan Bian, Ye Gao, Han Lin and Chang Sun contributed equally to this work.Department of Gastroenterology, Changhai Hospital...
Bortezomib-releasing silica-collagen xerogels for local treatment of osteolytic bone- and minimal residual disease in multiple myeloma
Bortezomib-releasing silica-collagen xerogels for local treatment of osteolytic bone- and minimal residual disease in multiple myeloma
Accumulation of malignant plasma cells in the bone marrow causes lytic bone lesions in 80% of multiple myeloma patients. F...
Asciminib add-on to imatinib demonstrates sustained high rates of ongoing therapy and deep molecular responses with prolonged follow-up in the ASC4MORE study
Asciminib add-on to imatinib demonstrates sustained high rates of ongoing therapy and deep molecular responses with prolonged follow-up in the ASC4MORE study
Up to 65% of patients with chronic myeloid leukemia (CML) who are treated with imatinib do not achieve sustained deep mole...
Engineering a controllable and reversible switch for CAR-based cellular immunotherapies via a genetic code expansion system
Engineering a controllable and reversible switch for CAR-based cellular immunotherapies via a genetic code expansion system
As one of the most promising adoptive cell therapies, CAR-T cell therapy has achieved notable clinical effects in patients...
Global burden of cancer and associated risk factors in 204 countries and territories, 1980–2021: a systematic analysis for the GBD 2021
Global burden of cancer and associated risk factors in 204 countries and territories, 1980–2021: a systematic analysis for the GBD 2021
Cancer is the second most common cause of death globally. Therefore, it is imperative to investigate cancer incidence, mor...
Evasion of immunosurveillance by the upregulation of Siglec15 in bladder cancer
Evasion of immunosurveillance by the upregulation of Siglec15 in bladder cancer
Immunotherapy resistance in bladder cancer (BLCA) is associated with elevated levels of sialic acid–binding immunogl...
A clinical study of autologous chimeric antigen receptor macrophage targeting mesothelin shows safety in ovarian cancer therapy
A clinical study of autologous chimeric antigen receptor macrophage targeting mesothelin shows safety in ovarian cancer therapy
CAR-macrophage has promising prospect in treating solid tumors, due to its high infiltration into tumors, and its dual rol...
Personalized nanovaccines for treating solid cancer metastases
Personalized nanovaccines for treating solid cancer metastases
Cancer vaccines have garnered attention as a potential treatment for cancer metastases. Nevertheless, the clinical respons...
The first-in-class bispecific antibody IBI318 (LY3434172) targeting PD-1 and PD-L1 in patients with advanced tumors: a phase Ia/Ib study
The first-in-class bispecific antibody IBI318 (LY3434172) targeting PD-1 and PD-L1 in patients with advanced tumors: a phase Ia/Ib study
There is an unmet clinical need to enhance the response rate and safety of anti-PD-1/PD-L1-based cancer immunotherapy (IO)...
Dynamically monitoring minimal residual disease using circulating tumour cells to predict the recurrence of early-stage lung adenocarcinoma
Dynamically monitoring minimal residual disease using circulating tumour cells to predict the recurrence of early-stage lung adenocarcinoma
Lung adenocarcinoma (LUAD) is one of the leading causes of cancer-related deaths worldwide, with a 5-year survival rate of...
Outcomes of patients with acute myeloid leukemia and bone marrow fibrosis
Outcomes of patients with acute myeloid leukemia and bone marrow fibrosis
The outcomes of patients with acute myeloid leukemia (AML) and bone marrow fibrosis (MF) are not well defined. The study o...
Menin inhibitors for the treatment of acute myeloid leukemia: challenges and opportunities ahead
Menin inhibitors for the treatment of acute myeloid leukemia: challenges and opportunities ahead
The AML treatment landscape has significantly changed in recent years with the approval of targeted therapies in the front...
In vivo gene editing and in situ generation of chimeric antigen receptor cells for next-generation cancer immunotherapy
In vivo gene editing and in situ generation of chimeric antigen receptor cells for next-generation cancer immunotherapy
Chimeric antigen receptor (CAR) cell therapy has achieved groundbreaking success in treating hematological malignancies. H...
RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms
RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms
Variants in the RAS family (HRAS, NRAS and KRAS) are among the most common mutations found in cancer. About 19% patients w...
Iparomlimab (QL1604) in patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) unresectable or metastatic solid tumors: a pivotal, single-arm, multicenter, phase II trial
Iparomlimab (QL1604) in patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) unresectable or metastatic solid tumors: a pivotal, single-arm, multicenter, phase II trial
Though several anti-PD-1/PD-L1 antibodies approved for monotherapy in microsatellite instability-high or mismatch repair-d...
Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies
Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies
Chimeric antigen receptor (CAR)-T cell therapy demonstrates substantial efficacy in various hematological malignancies. Ho...
A single-cell transcriptomic map of the murine and human multiple myeloma immune microenvironment across disease stages
A single-cell transcriptomic map of the murine and human multiple myeloma immune microenvironment across disease stages
The long-term effectiveness of immunotherapies against Multiple Myeloma (MM) remains elusive, demonstrated by the inevitab...
Hemophagocytic lymphohistiocytosis: current treatment advances, emerging targeted therapy and underlying mechanisms
Hemophagocytic lymphohistiocytosis: current treatment advances, emerging targeted therapy and underlying mechanisms
Hemophagocytic lymphohistiocytosis (HLH) is a rapidly progressing, life-threatening syndrome characterized by excessive im...
Prognostic impact of donor mitochondrial genomic variants in myelodysplastic neoplasms after stem-cell transplantation
Prognostic impact of donor mitochondrial genomic variants in myelodysplastic neoplasms after stem-cell transplantation
Mitochondrial DNA (mtDNA) variants in patients with myelodysplastic neoplasms (MDS) are shown to be prognostic of outcomes...
Tucidinostat plus pediatric-inspired chemotherapy for newly diagnosed adult ETP-ALL/LBL: a single-arm, phase 2 trial
Tucidinostat plus pediatric-inspired chemotherapy for newly diagnosed adult ETP-ALL/LBL: a single-arm, phase 2 trial
Early T-cell precursor lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) is a distinct subtype of T-ALL/LBL, characterized by ...
阅读更多
format_indent_increase